DYNC2I2

Across TCGA pan-cancer cohorts, DYNC2I2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DYNC2I2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DYNC2I2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DYNC2I2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where DYNC2I2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.895	0.374	.003	23	view →
PDAC	OS	Median	All	0.776	0.939	.016	5	view →
LUAD	DFS	Median	III,IV	0.409	0.922	.024	3	view →
LSCC	OS	Tertile	II,III,IV	0.885	1.000	.033	2	view →
HNSC	DFS	Quartile	IV	0.751	0.357	.034	2	view →
GBM	DFS	Median	All	0.681	0.815	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DYNC2I2–CCRCC (DFS)

Open the CCRCC breakdown →